MetaVia rises on regulatory nod to begin early-stage obesity trial

MetaVia

18/03/2026 12:41

** Shares of drug developer MetaVia MTVA.O rise 5.9% to $1.61 premarket

** Co says a U.S. Institutional Review Board has cleared its early-stage trial of its experimental dual-action obesity drug, DA‑1726

** The approval from the Institutional Review Board at Clinical Pharmacology of Miami allows co to start enrolling participants in the next portion of the early‑stage trial, which is designed to assess higher doses of the drug through two different titration regimens

** MetaVia says the Part 3 of early-stage trial will enroll 40 otherwise healthy adults with obesity

** The study will measure safety, tolerability, pharmacokinetics and pharmacodynamics of DA‑1726, an oxyntomodulin analog that targets GLP‑1 and glucagon receptor - MTVA

** Up to last close, stock has been down ~82% YTD

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))